For live biotherapeutics and microbiome products is estimated to be worth USD 300 million by 2030

Kevin Doe March 17, 2021 ·183 writeups ·joined Mar 2021

3 min read

Roots Analysis has done a detailed study on Live Biotherapeutic Products and Microbiome Contract Manufacturing Market, 2020-2030: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020-2030, covering key aspects of the industry’s evolution and identifying potential future growth opportunities.

To order this 300+ page report, which features 140+ figures and 125+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

Key Market Insights
The microbiome therapies pipeline features 260 drugs under evaluation across different phases of development; contract service providers have become an integral part of the supply chain owing to their technical expertise.
Presently, over 25 firms across the globe claim to possess the required know-how and infrastructure to offer contract manufacturing services for live biotherapeutic products and microbiome therapies
The market is fragmented, featuring the presence of established players and mid-sized firms across different global regions, with capabilities to manufacture aerobic and / or anaerobic strains, at varying scales of operation
Most of the installed, global live biotherapeutic contract manufacturing capacity presently belongs to dedicated large and mid-sized CMOs, accounting for over 90% of what is available across various geographies
Future growth of the market is likely to be driven by increased demand for these therapeutics; we expect the service-based revenues to grow at an annualized rate of over 46% in the coming decade
In the long-term, the projected market opportunity is anticipated to be well distributed across different types of formulations, sizes of contract service providers and geographical regions

For more information, please visit https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html

Table of Contents

1.PREFACE
1.1.Scope of the Report
1.2.Research Methodology
1.3.Chapter Outlines

2.EXECUTIVE SUMMARY

3.INTRODUCTION
3.1.Chapter Overview
3.2.Concept of Human Microbiota and Microbiome
3.3.Overview of Gut Flora
3.2.3.Role of Gut Flora in Healthy Individuals
3.2.4.Factors Affecting Human Gut Flora

3.4.The Human Microbiome Project (HMP)
3.5.Overview of Microbiome Therapies
3.5.1.Types of Microbiome Therapies
3.5.1.1.Probiotics
3.5.1.2.Prebiotics

3.5.2.Applications of Microbiome Therapies
3.5.3.Microbiome Therapies Supply Chain

3.6.Microbiome-based Product Manufacturing
3.6.1.Key Steps Involved
3.6.2.Associated Challenges
3.6.3.Role of Contract Manufacturing Organizations (CMOs)
3.6.4.Demand for Contract Manufacturing Services

3.7.Key Considerations for Selecting a Suitable CMO Partner
Contact Details